Objective To explore the efficacy and side effects of decitabine (DAC)combined with CAG regimen for high-risk myelodysplastic syndrome (MDS)and elderly acute myeloid leukemia (AML).Methods:A retrospec-tive analysis was performed on the efficiency and side effects of DAC combined with CAG regimen (DAC 25 mg qd,d1~5,Ara-C 10 mg/m2q12h,d6~12,Acla 12 mg/m2qd,d6~9,G-CSF 200 μg/m2qd,WBC>20×109/L then stop) for 26 cases of high-risk MDS and elderly AML.Results:Among the 26 cases of high-risk MDS and elderly AML,complete remission (CR)rate was 42.3%.The clinical efficiency (CR+PR)was 65.4%.None of the patients died early.Median survival time was 16.2 months.Conclusion:The DAC combined with CAG regimen for high-risk MDS and elderly AML patients had definite therapeutic effect,and high safety.Due to the small sample cohort,multicenter randomized controlled trial is necessary.%目的:探讨地西他滨(DAC)联合预激方案初次治疗高危骨髓增生异常综合征(MDS)及老年急性髓系白血病(AML)的疗效和不良反应.方法:回顾性分析首次接受DAC联合预激方案(DAC 25 mg qd,d1~5;Ara-C 10 mg/m2q12h,d6~12;Acla 12 mg/m2qd,d6~9;G-CSF 200 μg/m2qd,WBC>20×109/L则停用)治疗26例高危MDS及老年AML患者的疗效和不良反应.结果:26例高危MDS及老年AML患者中,完全缓解率42.3%,总体反应率(完全缓解+部分缓解)65.4%,中位生存时间为16.2个月.结论:DAC联合预激方案治疗高危MDS及老年AML患者疗效确切,且安全性高,但由于本研究样本量较小,需进一步开展多中心随机对照试验证实.
展开▼